Misery loves company, eh? What a haircut our Midwest biotech stocks took in the first half of the year.
Its virtually an across-the-board haircut that affected medical devices, specialty pharma, drug delivery and conventional biotech alike. Granted, many of the larger cap biotech stocks weathered the storm, but we have a few companies in the $2 billion range that also got short-circuited.
While this isnt a pretty picture, this is only the mid-year point (and of course oil prices keep rising). See you next week when we will focus on the progress of venture capital funding in the life science space in the first half of 2005.
Michael S. Rosen is president of Rosen Bioscience Management, a company that provides CEO services including financing, business and corporate development to start-up and early stage life science companies such as Renovar and Immune Cell Therapy. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at rosenmichaels@aol.com.
This article has been syndicated on the Wisconsin Technology Network courtesy of ePrairie, a user-driven business and technology news community distributed via the Web, the wireless Web and free daily e-mail newsletters.
The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect the views of The Wisconsin Technology Network, LLC. (WTN). WTN, LLC, accepts no legal liability or responsibility for any claims made or opinions expressed herein.
with HP SureSupply receive alerts when a cartridge is low, monitor remaining life, order online, and check stock at stores
- Get exclusive offers and discounts
[ Comment, Edit or Article Submission ]